When was Nautilus Biotechnology founded?

Nautilus Biotechnology was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Nautilus Biotechnology located?

Nautilus Biotechnology is headquartered in Seattle, United States. It is registered at 2701 Eastlake Avenue East Seattle, Washington.

Who is the current CEO of Nautilus Biotechnology?

Sujal Patel of Nautilus Biotechnology. They have also founded 2 companies and are an angel investors in 1 startup.

How many employees does Nautilus Biotechnology have?

As of Sep 30, 2026, the latest employee count at Nautilus Biotechnology is 148.

Is Nautilus Biotechnology a funded company?

Nautilus Biotechnology is a funded company, having raised a total of $453M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 30, 2018.

When was the latest funding round of Nautilus Biotechnology?

Nautilus Biotechnology's latest funding was a $***** Post IPO round on Aug 05, 2021, with participation from 1 investor.

Where does Nautilus Biotechnology rank among its competitors?

Nautilus Biotechnology ranks 1st amongst 179 active competitors, of which 30 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Arzeda, which secured $4.51M in Aug, 2025.

Who are the top competitors of Nautilus Biotechnology?

Nautilus Biotechnology's top competitors include Somalogic, Biognosys and Arzeda. Among them, Arzeda secured the most recent funding round in August, 2025.

Nautilus Biotechnology - 2026 Company Profile, Team, Funding, Competitors & Financials

Nautilus Biotechnology is a public company based in Seattle (United States), founded in 2016 by Sujal Patel and Parag Mallick. It operates as a Developer of proteomics platform for drug development. Nautilus Biotechnology has raised $453M in funding from Vulcan. The company has 179 active competitors, including 30 funded and 25 that have exited. Its top competitors include companies like Somalogic, Biognosys and Arzeda.

Company Details

Nautilus Biotechnology is developing a proteomics platform for analyzing and quantifying the human proteome. The company is developing a platform with sensitivity for protein quantification and analysis for the study of human proteins using its patent-protected technology. It is used for drug development and precision medicine.

Website: nautilus.bio
Social
Email ID: *****@nautilus.bio
Phone Number: +1 **********
Registered Address: 2701 Eastlake Avenue East Seattle, Washington

Key Metrics

Founded Year

2016

Location

Seattle, United States

Stage

Public

Total Funding

$453M in 5 rounds

Latest Funding Round

Post IPO, Aug 05, 2021, $*****

Investors

Vulcan & 9 more

Ranked

1^st among 179 active competitors

Employee Count

148 as on Sep 30, 2026

Similar Companies

Somalogic & 239 more

Exit Details

Public

View Nautilus Biotechnology's full profile

Nautilus Biotechnology is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Nautilus Biotechnology, Inc. CIN: 1808805 , United States, Active	Jun 08, 2021	-	-	-
NAUTILUS BIOTECHNOLOGY, INC CIN: 98-1541723 , United States, Active	Dec 31, 2015	-	134 (As on Dec 31, 2022)	-

Nautilus Biotechnology got listed on Jun 10, 2021.

Click here to take a look at Nautilus Biotechnology's IPO in detail

Nautilus Biotechnology has raised a total funding of $453M over 5 rounds. Its first funding round was on May 30, 2018. Its latest funding round was a Post IPO round on Aug 05, 2021 for $*****. 1 investor participated in its latest round. Nautilus Biotechnology has 10 institutional investors.

Here is the list of recent funding rounds of Nautilus Biotechnology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 05, 2021	1805487	Post IPO	7233775	5446021	7459033	6090897
Jun 22, 2021	6661876	Post IPO	9867215	6381350	5191595	8117080
Feb 08, 2021	5524561	Series C	2716857	1474495	1252319	9590527

Access funding benchmarks and valuations. Sign up today!

View details of Nautilus Biotechnology's funding rounds and investors

The founders of Nautilus Biotechnology are Sujal Patel and Parag Mallick. Sujal Patel is the CEO of Nautilus Biotechnology.

Here are the details of Nautilus Biotechnology's key team members:

Sujal Patel: Co-Founder & CEO of Nautilus Biotechnology and founder of 1 other company. They are also an angel investor in 1 startup and serve on the boards of 2 companies.
Parag Mallick: Co-Founder of Nautilus Biotechnology.
Contact Info: 1 email address

View details of Nautilus Biotechnology's Founder profiles and Board Members

Nautilus Biotechnology's employee count trend

Nautilus Biotechnology has 148 employees as of Sep 26. Here is Nautilus Biotechnology's employee count trend over the years:

Employee count trend for Nautilus Biotechnology

Uncover Nautilus Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nautilus Biotechnology include Somalogic, Biognosys and Arzeda. Here is the list of Top 10 competitors of Nautilus Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nautilus Biotechnology 2016, Seattle (United States), Public	Developer of proteomics platform for drug development	$453M	Bain Capital Life Sciences, Perceptive Advisors ... & 8 others	67/100
2nd	Somalogic 1999, Boulder (United States), Acquired	Developer of protein-based assays for life science research	$664M	ProQuest Investments, ICarbonX & 27 others	64/100
3rd	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Syngenta Group, Zurcher Kantonalbank & 6 others	63/100
4th	Arzeda 2008, Seattle (United States), Series B	Developer of enzyme design technology to bridge the gap by creating synthetic enzymes	$95.2M	OS Fund, Conti Ventures & 22 others	59/100
5th	A-Alpha Bio 2017, Seattle (United States), Series A	Developer of cell-based tool for the measurements of protein interactions	$45.2M	Xontogeny, OS Fund & 15 others	57/100
6th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
7th	ProteinSimple 2004, San Jose (United States), Acquired	Provider tools to help researchers with protein analysis	$94.3M	Lansing Brown Investments, Royal Bank of Canada ... & 10 others	54/100
8th	Amunix 2006, Mountain View (United States), Acquired	Developer of peptide-based therapeutics	$201M	Omega Funds, Frazier Healthcare Partners ... & 18 others	49/100
9th	Akonni 2003, Frederick (United States), Series C	Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification	$39.7M	Righton, Choosemaryland.org & 5 others	49/100
10th	Dynamic Biosensors 2011, Planegg (Germany), Acquired	Provides solutions for label-free molecular interaction and biophysical analysis	$5.83M	Rurode, UVC Partners & 19 others	49/100